<DOC>
	<DOC>NCT01615198</DOC>
	<brief_summary>The purpose of this study is to access the efficacy and safety of LCZ696 compared to olmesartan in elderly Asian patients for the treatment of hypertension.</brief_summary>
	<brief_title>Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Patients must give written informed consent before any assessment is performed Patients with essential hypertension, untreated or currently taking antihypertensive therapy must have a mean sitting systolic blood pressure ≥ 150 mmHg and &lt; 180 mmHg Patients must be able to communicate and comply with all study requirements and demonstrate good medication compliance Exclusion criteria: Patients with severe hypertension (msDBP ≥ 110 mmHg and/or msSBP ≥180 mmHg). Patients with history of angioedema, drugrelated or otherwise Patients with history or evidence of a secondary form of hypertension Transient ischemic cerebral attack (TIA) during the 12 months prior to Visit 1 or any history of stroke History of myocardial infarction, coronary bypass surgery or any percutaneous coronary intervention (PCI) during the 12 months prior to Visit 1. Current angina pectoris requiring medication (other than patients on a stable dose of oral or topical nitrates). Patients with Type 1 or Type 2 diabetes mellitus who are not well controlled and are not on a stable dose of antidiabetic medication Patients with previous or current diagnosis of heart failure (NYHA Class IIIV). Patients with a clinically significant valvular heart disease at the time of screening Women of childbearing potential, who do not use adequate birth control methods Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hypertension, blood pressure, LCZ696, dual inhibitor, neprilysin, NEP inhibition, vasopeptidase, ARNi, angiotensin receptor</keyword>
</DOC>